Clinical trials of psilocybin, MDMA, DMT, and ketamine, from the early NYU cancer-anxiety studies to psilocybin for OCD at Yale. Fifteen-plus
peer-reviewed papers, including in Nature Medicine (2025), three book chapters, and
two books.
2018 – 2025 Yale University, Co-Investigator, Efficacy of Psilocybin in OCD: a double-blind, placebo-controlled study.
2020 – 2023 Cybin, Chief Clinical Officer. Led clinical development of psilocybin and DMT analogues; program contributed to FDA Breakthrough Therapy Designation; met with FDA, Health Canada, and MHRA.
2017 – 2020 MAPS, Study therapist & sub-investigator, FDA Phase 3 trial of MDMA-assisted psychotherapy for severe PTSD.
2020 – 2021 Nautilus Sanctuary, Founding President of an early nonprofit center for psychedelic medicine on the East Coast.
2006 – 2020 NYU Psychedelic Research Group, Founding member; administrative director of the landmark psilocybin cancer-anxiety trial; lead investigator of its qualitative studies.
Grants
Heffter Research Institute (2013). Patient experiences of psilocybin-assisted psychotherapy. Lead Investigator · $50,000 · New York University
Robert Wood Johnson Foundation (2005–2007). Developing a Relational Inquiry Tool for probation and parole. Grant writer/contributor · $200,000 · Vera Institute of Justice